BCAX BICARA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BICARA THERAPEUTICS INC reported revenue of n/a, net income of −$55.4M and diluted EPS of −$0.82; for the fiscal year ended December 2025 revenue was n/a.
BCAX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$156M, net income −$138M (margin n/a), EPS −$2.52
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$82.4M, net income −$68.0M (margin n/a), EPS −$4.05
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$39.9M, net income −$52.0M (margin n/a), EPS −$89.61
BCAX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$55.4M, EPS −$0.82
- Quarter ended Mar 31, 2026: revenue n/a, net income −$56.2M, EPS −$0.93
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$37.4M, EPS −$0.67
- Quarter ended Sep 30, 2025: revenue n/a, net income −$36.3M, EPS −$0.67
- Quarter ended Jun 30, 2025: revenue n/a, net income −$27.4M, EPS −$0.50
- Quarter ended Mar 31, 2025: revenue n/a, net income −$36.8M, EPS −$0.68
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$21.0M, EPS $35.50
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.5M, EPS −$1.60
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.0M, EPS −$19.01
- Quarter ended Mar 31, 2024: revenue n/a, net income −$12.5M, EPS −$18.94
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.4M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$22.8M, EPS −$38.23
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.29M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.41M, EPS n/a
BCAX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$107M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$74.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$45.6M, share buybacks n/a
BCAX balance sheet
- Jun 30, 2026: cash $96.6M, total assets $512M, total liabilities $43.5M, shareholders' equity $469M
- Mar 31, 2026: cash $323M, total assets $554M, total liabilities $39.6M, shareholders' equity $514M
- Dec 31, 2025: cash $96.7M, total assets $431M, total liabilities $29.5M, shareholders' equity $401M
- Sep 30, 2025: cash $172M, total assets $425M, total liabilities $21.9M, shareholders' equity $403M
- Jun 30, 2025: cash $437M, total assets $454M, total liabilities $18.4M, shareholders' equity $435M
- Mar 31, 2025: cash $462M, total assets $478M, total liabilities $19.1M, shareholders' equity $459M
- Dec 31, 2024: cash $490M, total assets $510M, total liabilities $18.1M, shareholders' equity $492M
- Sep 30, 2024: cash $521M, total assets $524M, total liabilities $14.6M, shareholders' equity $510M
Is BCAX profitable?
No. BICARA THERAPEUTICS INC lost $185M over the last four quarters.
What is BCAX's EPS?
Diluted earnings per share over the last four quarters were −$3.09; −$0.82 in the latest quarter.